In 2007 a new family of triazole NNRTIs was presented by researchers from the pharmaceutical company Ardea Biosciences. The selected candidate from the screening executed was RDEA806 belonging to the family of triazoles. It has similar resistance profile against selected NNRTI resistant HIV-1 strains to other next generation NNRTIs. The candidate entered phase IIb clinical trials in the end of 2009, but no further trial have been initiated. Ardea was sold to AstraZeneca in 2012.